The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Table 4 Tumor response at 6 months in the two treatment groups in patients with and without PVTT

Tumor response	No PVTT		P	PVTT types I, II, III and IV		P
Tumor response	Sorafenib group (n = 19)	TACE + sorafenib group (n = 24)	P	Sorafenib group (n = 21)	TACE + sorafenib group (n = 24)	P
CR, n (%)	2 (10.53%)	3 (12.5%)	1.000	0 (0%)	0 (0%)	-
PR, n (%)	2 (10.53%)	2 (8.33%)	1.000	1 (4.76%)	4 (16.67%)	0.352
SD, n (%)	10 (52.63%)	8 (33.33%)	0.203	8 (38.1%)	10 (41.67%)	0.807
PD, n (%)	5 (26.32%)	11 (45.83%)	0.189	12 (57.14%)	10 (41.67%)	0.300
OR, n (%)	4 (21.06%)	5 (20.83%)	1.000	1 (4.76%)	4 (16.67%)	0.352

CR complete response, OR overall response (CR + PR), PD progressive disease, PR partial response, SD stable disease

ISSN: 1471-2407